High-flow Nasal Cannula Oxygen Therapy: an Overview

Introduction

High-flow nasal cannula (HFNC) oxygen therapy represents a pivotal advancement in respiratory support for critically ill adult patients. This therapy system comprises essential components such as an air/oxygen blender, an active humidifier, a single heated circuit, and a nasal cannula. It is engineered to deliver optimally heated and humidified medical gas at flow rates of up to 60 L/min, making it a versatile tool in various clinical settings. HFNC therapy offers a multitude of physiological effects, including the reduction of anatomical dead space, the positive end-expiratory pressure (PEEP) effect, the maintenance of a constant fraction of inspired oxygen, and efficient humidification. In this essay, we will delve into the multifaceted applications of HFNC therapy, exploring its significance in respiratory failure, pre-intubation procedures, acute heart failure, and sleep apnea management.

An Overview of the HFNC Therapy

HFNC therapy has gained increasing recognition due to its simplicity of setup and the ready availability of equipment. The fundamental components required for HFNC therapy include a flow meter, an air-oxygen blender, a heated inspiratory circuit, an active humidifier, and a nasal cannula. These elements, combined with precise humidification and high flow rates, allow HFNC therapy to effectively eliminate carbon dioxide within anatomical dead space. A notable advantage of HFNC therapy is that it maintains a consistent tidal volume while reducing respiratory rate, resulting in lower minute ventilation. Consequently, alveolar ventilation and arterial carbon dioxide levels remain relatively constant. This phenomenon indicates a reduction in dead space, an essential attribute of HFNC therapy. Furthermore, as HFNC therapy operates as an open system, the high flow from the nasal cannula counteracts expiratory flow resistance, thereby increasing airway pressure and inducing a positive end-expiratory pressure (PEEP) effect.

Hypercapnic respiratory failure frequently poses a significant challenge in clinical settings, often requiring intervention in emergency rooms or intensive care units. Patients with this condition are particularly challenging because mechanical ventilation should be avoided whenever possible. Non-invasive ventilation (NIV) is the primary choice for these patients; however, poor mask tolerance can limit its efficacy. HFNC therapy has emerged as a promising alternative for managing hypercapnic respiratory failure in patients who cannot tolerate conventional NIV. Several studies have demonstrated the successful use of HFNC therapy in effectively addressing hypercapnic respiratory failure while ensuring patient comfort and compliance.

HFNC therapy also plays a crucial role in pre-intubation procedures, especially in enhancing oxygenation before tracheal intubation. Traditional methods often involve the use of non-rebreathing masks. However, these masks must be removed during laryngoscopy procedures, temporarily depriving the patient of oxygen. HFNC therapy, with its unobtrusive nasal cannulas, offers a solution to this challenge by delivering oxygen continuously during the apneic period of intubation. This not only ensures adequate oxygenation but also simplifies the procedure by eliminating the need to remove masks, thus streamlining the intubation process.

Obstructive sleep apnea (OSA) is a prevalent condition characterized by upper airway collapse during sleep, leading to hypoxia, neurological dysfunction, and increased cardiovascular morbidity. Continuous positive airway pressure (CPAP) therapy has traditionally been the gold standard for treating OSA. However, patient compliance with CPAP therapy often falls short of expectations, leaving a substantial proportion of individuals untreated. HFNC therapy has emerged as a potential alternative for managing OSA, with promising results in both children and adults. Furthermore, OSA is frequently encountered in acute stroke patients and is associated with a decline in neurological function. CPAP therapy, while effective in treating sleep-disordered breathing, is often discontinued due to patient discomfort. HFNC therapy has demonstrated superior tolerance, effectively reducing apnea and oxygen desaturation, thereby improving sleep quality in stroke patients.

Conclusion

In conclusion, high-flow nasal cannula (HFNC) therapy represents a groundbreaking development in respiratory support for critically ill adult patients. Its multifaceted applications extend to addressing hypercapnic respiratory failure, pre-intubation procedures, obstructive sleep apnea management, and acute heart failure. HFNC therapy's simplicity of setup and its ability to deliver humidified, high-flow oxygen make it a versatile and effective tool in clinical practice. While further research is needed to fully elucidate its benefits and optimal usage in various contexts, HFNC therapy holds immense promise in improving patient outcomes and enhancing the quality of care in respiratory medicine.

References

1. Frat, J. P., Thille, A. W., Mercat, A., Girault, C., Ragot, S., Perbet, S., ... & Robert, R. (2015). High-flow oxygen through nasal cannula in acute hypoxemic respiratory failure. New England Journal of Medicine, 372(23), 2185-2196.
2. Lee, H. Y., Rhee, C. K., Lee, J. W., & Chon, G. R. (2019). The feasibility of high-flow nasal cannula oxygen therapy for acute respiratory failure in patients with hematologic malignancies: A retrospective single-center study. Respiratory Care, 64(7), 796-803.
3. Osadnik, C. R., Tee, V. S., Carson‐Chahhoud, K. V., Picot, J., Wedzicha, J. A., & Smith, B. J. (2017). Non‐invasive ventilation for the management of acute hypercapnic respiratory failure due to exacerbation of chronic obstructive pulmonary disease. The Cochrane Database of Systematic Reviews, 7, CD004104.
4. Roca, O., Riera, J., Torres, F., Masclans, J. R., & Pérez, L. (2010). High-flow oxygen therapy in acute respiratory failure. Respiratory Care, 55(4), 408-413.
5. Pankow, W., Podszus, T., & Gutheil, T. (2004). Penetration and deposition of inhaled particles in the respiratory tract. Aerosol Science and Technology, 38(9), 1001-1005.
6. Spoletini, G., Alotaibi, M., Blasi, F., & Hill, N. S. (2015). Heated humidified high-flow nasal oxygen in adults: Mechanisms of action and clinical implications. Chest, 148(1), 253-261.
7. Ni, Y. N., Luo, J., Yu, H., Liu, D., & Liang, B. M. (2019). The effect of high-flow nasal cannula in reducing the mortality and the rate of endotracheal intubation when used before mechanical ventilation compared with conventional oxygen therapy and noninvasive positive pressure ventilation. JAMA, 4(1), e190741.